Oncolytics Biotech
ONCY
33 hedge funds and large institutions have $13.6M invested in Oncolytics Biotech in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.
542% more capital invested
Capital invested by funds: $2.11M → $13.6M (+$11.4M)
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
7.32% more ownership
Funds ownership: 1.27% → 8.59% (+7.3%)
3% more funds holding
Funds holding: 32 → 33 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$13M |
| 2 |
Millennium Management
New York
|
+$520K |
| 3 |
LPL Financial
San Diego,
California
|
+$52.7K |
| 4 |
AFP
Ausdal Financial Partners
Davenport,
Iowa
|
+$48.9K |
| 5 |
BAM
Brave Asset Management
Summit,
New Jersey
|
+$36.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$297K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$112K |
| 3 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
-$49.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$14.1K |
| 5 |
DI
Disciplined Investments
Tulsa,
Oklahoma
|
-$13.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IA
26
IFP Advisors
Tampa,
Florida
| $4.36K | +$4.89K | +2,000 | New |
|
27
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2.61K | +$2.92K | +1,196 | New |
|
28
Barclays
London,
United Kingdom
| $1.74K | +$1.95K | +800 | New |
|
|
TWC
29
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $1.57K | – | – | – |
|
|
JFA
30
JNBA Financial Advisors
Bloomington,
Minnesota
| $458 | – | – | – |
|
|
CCMW
31
Cypress Capital Management (Wyoming)
Sheridan,
Wyoming
| $218 | – | – | – |
|
|
WWM
32
Wolff Wiese Magana
Carslbad,
California
| $68 | – | – | – |
|
33
1832 Asset Management
Toronto,
Ontario, Canada
| $10 | – | – | – |
|
|
NDSI
34
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
| – | -$49.2K | -18,915 | Closed |
|
|
DI
35
Disciplined Investments
Tulsa,
Oklahoma
| – | -$13.5K | -5,189 | Closed |
|
|
TRCT
36
Tower Research Capital (TRC)
New York
| – | -$6.86K | -2,639 | Closed |
|
|
CWA
37
Clearview Wealth Advisors
Salem,
Oregon
| – | -$1.3K | -500 | Closed |
|
|
NC
38
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$572 | -220 | Closed |
|
ONCY Hedge Fund Activity: Q3 2023 in Review
33 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2023, worth a combined $13.6M — up 542% from $2.11M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ONCY positions and 6 closed out — a net gain of 2 holders — while 8 added to existing stakes and 5 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $13M. The largest seller was Morgan Stanley, cutting an estimated $297K.
- 33 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2023, up from 32 in Q2 2023.
- Funds reported $13.6M of Oncolytics Biotech stock for Q3 2023, up 542% quarter-over-quarter.
- 8 funds opened new Oncolytics Biotech positions in Q3 2023 and 6 closed out, a net change of +2 holders.
- The largest Oncolytics Biotech buyer in Q3 2023 was Anson Funds Management, an estimated $13M added.
- The largest Oncolytics Biotech seller in Q3 2023 was Morgan Stanley, an estimated $297K sold.
Based on aggregated 13F filings for Q3 2023.